Between 7 and 29 percent of people on statins report muscle aches, weakness or cramping, and it is one of the biggest reasons patients quit these life-extending cholesterol drugs. New laboratory research from McMaster University in Canada may finally explain what the pill is doing to muscle tissue, and it points to a way to stop the damage without touching the heart benefit.
In a study published in Science Advances in 2026, the Schertzer Lab reported that statins interfere with the way muscle cells generate energy, and that this metabolic stress triggers an immune reaction inside the muscle itself. Blocking that reaction, in cells and in mice, prevented much of the damage.
Where the trouble starts
The finding involves a molecular alarm called the NLRP3 inflammasome, a sensor the body normally uses to detect danger and switch on inflammation. According to the McMaster team's paper, statins lower a process called protein prenylation, which slows sugar-burning in muscle cells and flips that alarm on. Once activated, NLRP3 drives muscle wasting and lowers protein production, the biological signature of statin myopathy.
Crucially, the researchers showed the damage pathway can be interrupted. Restoring the missing lipid building blocks, activating a related growth signal called YAP, or directly blocking NLRP3 all reduced muscle atrophy in the lab models. The cholesterol-lowering job of statins runs on a separate branch of the same chemistry, which is why the team believes a future drug could shield muscle without dulling the cardiovascular effect.
Also read: Check your cabinet: FDA found a banned pesticide in diet pill
"One of the most exciting findings of the research is that the mechanism causing muscle side-effects appears to be separate from the mechanism that lowers cholesterol," said Jonathan Schertzer, a professor in McMaster's Department of Biochemistry and Biomedical Sciences who led the work.
Not the only theory on the table
The McMaster paper is not the only recent attempt to unpack statin muscle pain. In a paper published in the Journal of Clinical Investigation in late 2025 and highlighted by ScienceDaily in January 2026, a Columbia University team described a separate mechanism, showing that simvastatin binds directly to the ryanodine receptor on muscle cells and lets calcium leak into places it does not belong, which over time can weaken or degrade muscle fibers.
Andrew Marks, chair of physiology and cellular biophysics at Columbia, told ScienceDaily that any explanation is likely to cover only part of the patient population, but that even a partial fix would matter. "It is unlikely that this explanation applies to everyone who experiences muscular side effects with statins, but even if it explains a small subset, that's a lot of people we could help if we can resolve the issue," he said.
What it means for patients right now
Neither finding changes what is available at the pharmacy today. Both are preclinical, based on cell cultures and mouse models, and any candidate drug that spares muscle would need years of human trials before reaching cardiology clinics. The Columbia group has pointed to experimental compounds that close the calcium leak, already in trials for rare muscle diseases, as a plausible starting point.
Also read: A pig kidney kept him alive for 271 days - now he has a human one
For anyone currently on a statin and struggling with muscle symptoms, the standing clinical advice has not changed. Patients should not stop the medication on their own, but raise the side effect with the prescribing doctor, who can adjust the dose, switch to a different statin or investigate other causes before ruling the drug out.
Also read: These foods may support better sleep
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.